Global Cancer Cachexia Market By Therapeutics (Progesterone, Corticosteroids, Combination Therapies, and Others), By Mode of Action (Appetite Stimulators, Weight Loss Stabilizers, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032.

Report Overview

The global cancer cachexia market size is expected to be worth around USD 4034 Mn by 2032 from USD 2,554 Mn in 2022, growing at a CAGR of 4.8% during the forecast period from 2022 to 2032.

Cancer cachexia refers to a loss of appetite and muscle atrophy, host-phagocytic, multi-factorial, involuntary loss of lean body mass, negative protein balance, and wasting syndrome characterized by systematic inflammation.

It is due to the occurrence of different chronic diseases such as Human Immunodeficiency Virus (HIV), multiple sclerosis, tuberculosis (TB), and Chronic Obstructive Pulmonary Disease (COPD). Cancer cachexia can be treated with various therapeutics, such as combination therapy, corticosteroid, and progestogen.

Amongst these therapeutics, progesterone is a natural or synthetic steroid hormone that promotes weight gain and improves appetite, and however corticosteroid assists in suppressing overactive immune systems and mitigating inflammation.

Key Takeaways

• Market Growth: Cancer cachexia market set to grow at 4.8% CAGR, reaching USD 4,034 Mn by 2032 from USD 2,554 Mn in 2022.
• Progesterone Dominance: Progesterone therapy leads with a 5.4% CAGR, considered the safest option for cancer cachexia treatment in 2022.
• Hospital Pharmacy: In 2022, hospital pharmacies held the largest market share due to increased hospitalization cases.
• Weight Loss Stabilizers: This segment, with a 4.2% CAGR, is essential for countering weight loss and improving patients’ quality of life.
• Cancer Frequency: Rising cancer cases worldwide boost the market; WHO reported 18.1 million new cases in 2018.
• Opportunity: Product Pipeline: Growing relevance of cancer and cachexia drives R&D, leading to a strong product pipeline for therapeutic drugs.
• Combination Therapy: Healthcare professionals adopt combination therapies for better outcomes, increasing popularity in the market.
• Regional Dominance: North America holds over 45.1% market share, while APAC is set to grow at a higher CAGR.

Therapeutics Analysis

In 2022, progesterone held the highest market share in the cancer cachexia market and was expected to grow at a CAGR of 5.4% during the forecast period of 2023-2032. The market was due to factors such as the safest and most effective option for pain-free treatment of cancer cachexia.

Therefore, it will play a vital role in the progestogens segment to maintain its position in the market. Current therapies focus on reducing the distress of patients and families and palliating the treatment of cancer cachexia.

Despite that, combination therapies are estimated to be the fastest segment because they widely use novel pharmaceutical agents such as omega-3 fatty acid, megestrol acetate, ghrelin, and medroxyprogesterone. Reportedly these agents have improved survival rates as well as the quality of life.

Distribution Channel Analysis

Among distribution channels, the market is segmented into online pharmacy, retail pharmacy, and hospital pharmacy. In 2022, Hospital Pharmacy Segment held the largest share owing to the higher number of hospitalization cases.

The dominance is due to increased hospitalization of patients with Cancer and other related disorders such as cachexia. Therefore, the hospital pharmacy segment is expected to generate a dominant Cancer Cachexia Market share throughout the forecast period.

Mode of Action Analysis

During the forecast period of 2023-2032, weight loss stabilizers hold a significant share of the cancer cachexia market in 2022 and are expected to grow at a CAGR of 4.2%. Inflammatory cytokines, tissue wasting, wasting syndrome, and cystic fibrosis are the main problems in cancer cachexia. Anorexia nervosa is an eating disorder that results in weight loss.

In cancer cachexia, countering weight loss is vital in improving the quality of life in the patients. Cancer cachexia is characterized by the notable to chemotherapy and radiotherapy, unhindered loss of muscles which may cause death, and poor tolerance of antitumor treatments.

Around half of all cancer patients experience cachexia, with a sign up to 85% in the last 1 to 2 weeks of life, and 45% of patients lose above 10% of their original body weight during disease advancement. Thus, doctors are recommending the use of weight stabilizers to prevent patients from cancer cachexia.

Key Market Segments

Based on Therapeutics

• Progestogens
• Corticosteroids
• Combination Therapies
• Others

Based on Distribution Channel

• Hospital
• Retail Pharmacy
• Online Pharmacy

Based on the Mode of action

• Appetite Stimulators
• Weight Loss Stabilizers
• Others

Drivers

Increasing Frequency of Cancer

Worldwide, the rising frequency of Cancer increases the incidence of cachexia. Therefore, it drives the market, as many patients seek effective treatment. For instance, as per the estimations of the WHO, in 2018, around 18.1 million new cancer cases were reported globally.

Also, as per the report of the SCWD (Society on Sarcopenia, Cachexia, and Wasting Disorders) in 2018, in developed countries, approximately 0.4-1.0% of all overpopulation in developed countries were suffering from cachexia, which also includes cancer-induced cachexia.

Lack of approval of the drug for cachexia treatment

The lack of approval of the drug for cachexia treatment in patients and monotherapy administration with corticosteroids and progestogens has led doctors and cancer patients to find alternative therapeutic approaches.

Therefore, the industry is gaining traction through a combination of nutritional and medical therapeutic interventions. These therapies provide better profiles of safety as well as efficacy.

As a result, companies are increasing the availability of drugs and research and development for cancer cachexia treatment. These initiatives facilitate their adoption among patients.

It is expected that this innovation will have a positive impact on overall market growth.

Restraints

Strict regulatory requirements and lengthy FDA approval procedure

Due to the lengthy FDA approval procedure and strict regulatory requirements, cancer cachexia drug manufacturers are discouraged from investing in the market, which impedes the long-term growth of this market. Furthermore, cancer medications have therapeutic effects and related side effects.

Therefore, it is essential to monitor closely that the adverse effects do not surpass the therapeutic effects. Thus, the market for cancer cachexia drugs is restrained due to the stringent regulatory authorities.

Opportunity

The increasing relevance of cancer and cancer cachexia patients

The demand for treatment and drugs has increased because of factors like the increasing significance of Cancer and cancer cachexia in patients. This rising demand for therapeutics in the market has to speed up R&D activities in order to develop novel therapeutic drugs.

It results in the creation of a strong product pipeline consisting of different therapy products. These factors have been the main reason for the development of the market.

Also, advancement related to treating cancer cachexia and increased awareness of this syndrome has helped the market grow. The growing potential of new chromatography agents has been highlighted due to randomized trials.

The positive impact due to the use of combination chemotherapy in the adjuvant setting for improving survival rate is occurring. Due to growing awareness about improving the quality of life for cancer patients, the cancer cachexia market will gather a significant pace.

By using pharmacological treatments with diverse chemical compounds, researchers are experimenting in search of specific drugs to cure this syndrome. The NSAIDs (Non-steroidal anti-inflammatory drugs) have shown expected results in this scenario.

Trends

Approach toward combination therapy

In most cases, the traditional methods are implemented to treat the patient with a single drug intervention. It results in a decrease in clinical outcomes. Due to the lack of drug approval for the condition, Healthcare professionals are approaching combination therapies for treatment, including pharmacological and non-pharmacological therapies.

The marked improvement was shown by clinical trials in Lean Body Mass (LBM) of patients treated with combination therapies. It increases popularity among healthcare professionals and boosts the implementation of combination therapies among patients. It fuels the demand for the global cancer cachexia market.

Regional Analysis

North America dominates the global cancer cachexia market.

North America dominated the cancer cachexia market with a share above 45.1%. The advancing paradigm of care for cancer patients and the presence of many drug manufacturers are supporting the growth in this region.

In addition, advancements in a robust product pipeline for wasting syndrome and novel technology for treating cancer cachexia have also helped enhance the cancer cachexia market in the region.

During the forecast period, APAC is expected to grow at a higher CAGR. It is because of the growing geriatric populations in countries such as China and Japan and increasing awareness about cancer-supportive care among healthcare professionals and people.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The present market owes to some players operating the market due to the absence of approved therapeutics, especially for treating cancer cachexia. Therefore, it represents a vast market growth opportunity for the other players to occupy a dominant market share by initiating new products. Likely, OHR/AVR118 is being studied by Ohr Pharmaceutical Inc. and is presently in Phase 2 clinical trials for study in advanced cancer patients along with cachexia.

A few major players in the market include Pfizer Inc., Aavogen Inc., Merck & Co. Inc., Artelo Biosciences Inc., Alder BioPharmaceuticals Inc., Helsinn Healthcare SA,  AVEO Pharmaceuticals, Inc., GTx Inc., Fresenius SE, Aeterna Zentaris, and others.

Listed below are some of the most prominent global cancer cachexia players.

Market Key Players

• Eli Lilly and Company
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• ANI Pharmaceuticals
• Hikma Pharmaceuticals PLC
• SkyePharma
• Other Key Players

Recent Developments

• In April 2021, a Swiss pharmaceutical, Helsin, and its partner, Ono pharmaceuticals, announced the launch of Adlumiz Tablets for cancer cachexia in Japan.
• In April 2021, Actimed Therapeutics Ltd announced a license agreement for S-oxprenolol to Faraday Pharmaceuticals, Inc.
• In February 2021, Trinity researchers announced its partnership with Artelo Biosciences to expand and investigate a new treatment for cancer cachexia.

Report Scope